Why Moleculin Biotech's Stock Is Trading Higher Today

Moleculin Biotech Inc MBRX shares are trading higher on Wednesday, after the company said that independent research found 2-deoxy-D-glucose (2-DG) to reduce replication of coronavirus by 100% in the Vitro Testing.

The company also noted the 2-DG is an active compound in its WP1122 Drug.

See Also: Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort

Moleculin Biotech is a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and lung-localized tumors.

Moleculin Biotech shares were trading higher by 170.13% to $1.52 at the time of publication. The stock has a 52-week high of $3.15 and a 52-week low of 32 cents.

Posted In: NewsPenny StocksMarketswhy it's moving
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...